 CSL Behring and uniQure N.V.s NASDAQ: QURE etranacogene dezaparvovec, a hemophilia B gene therapy, achieved the pre-specified primary endpoint of non-inferiority in annualized bleeding rate ABR compared to baseline Factor IX FIX prophylactic treatment. 